You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerindopril
Accession NumberDB00790  (APRD01178)
TypeSmall Molecule
GroupsApproved
DescriptionPerindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Structure
Thumb
Synonyms
(2S,3AS,7as)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
Perindoprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AceonTablet2 mg/1OralXOMA (US) LLC1993-12-30Not applicableUs
AceonTablet2 mg/1OralSymplmed, LLC2014-10-10Not applicableUs
AceonTablet4 mg/1OralXOMA (US) LLC1993-12-30Not applicableUs
AceonTablet4 mg/1OralSymplmed, LLC2014-10-10Not applicableUs
AceonTablet8 mg/1OralXOMA (US) LLC1993-12-30Not applicableUs
AceonTablet8 mg/1OralSymplmed, LLC2014-10-10Not applicableUs
ArcosylTablet, orally disintegrating10 mgOralServier Canada IncNot applicableNot applicableCanada
ArcosylTablet5 mgOralServier Canada IncNot applicableNot applicableCanada
ArcosylTablet10 mgOralServier Canada IncNot applicableNot applicableCanada
ArcosylTablet, orally disintegrating2.5 mgOralServier Canada IncNot applicableNot applicableCanada
ArcosylTablet2.5 mgOralServier Canada IncNot applicableNot applicableCanada
ArcosylTablet, orally disintegrating5 mgOralServier Canada IncNot applicableNot applicableCanada
CoversylTablet4 mgOralServier Canada Inc1994-12-31Not applicableCanada
CoversylTablet2 mgOralServier Canada Inc1994-12-31Not applicableCanada
CoversylTablet8 mgOralServier Canada Inc2003-09-11Not applicableCanada
Perindopril ErbumineTablet4 mg/1OralLannett Company, Inc.2014-10-01Not applicableUs
Perindopril ErbumineTablet8 mg/1OralLannett Company, Inc.2014-10-01Not applicableUs
Perindopril ErbumineTablet4 mg/1OralMarlex Pharmaceuticals Inc2015-05-01Not applicableUs
Perindopril ErbumineTablet8 mg/1OralMarlex Pharmaceuticals Inc2015-05-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-perindoprilTablet8 mgOralApotex Inc2007-02-02Not applicableCanada
Perindopril ErbumineTablet2 mg/1OralAurobindo Pharma Limited2009-11-10Not applicableUs
Perindopril ErbumineTablet2 mg/1OralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril ErbumineTablet2 mg/1OralWest Ward Pharmaceuticals Corp.2009-11-10Not applicableUs
Perindopril ErbumineTablet4 mg/1OralAurobindo Pharma Limited2009-11-10Not applicableUs
Perindopril ErbumineTablet4 mg/1OralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril ErbumineTablet4 mg/1OralWest Ward Pharmaceuticals Corp.2009-11-10Not applicableUs
Perindopril ErbumineTablet8 mg/1OralAurobindo Pharma Limited2009-11-10Not applicableUs
Perindopril ErbumineTablet8 mg/1OralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril ErbumineTablet8 mg/1OralWest Ward Pharmaceuticals Corp.2009-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CoversylServier
Brand mixtures
NameLabellerIngredients
Arcosyl PlusServier Canada Inc
Arcosyl Plus LdServier Canada Inc
Coversyl PlusServier Canada Inc
Coversyl Plus HdServier Canada Inc
Coversyl Plus LdServier Canada Inc
PrestaliaSymplmed Pharmaceuticals, Llc
ViacoramServier Canada Inc
Salts
Name/CASStructureProperties
Perindopril arginine
612548-45-5
Thumb
  • InChI Key: RYCSJJXKEWBUTI-YDYAIEMNSA-N
  • Monoisotopic Mass: 542.342797845
  • Average Mass: 542.678
DBSALT001144
Perindopril erbumine
107133-36-8
Thumb
  • InChI Key: IYNMDWMQHSMDDE-MHXJNQAMSA-N
  • Monoisotopic Mass: 441.320271497
  • Average Mass: 441.613
DBSALT001145
Categories
UNIIY5GMK36KGY
CAS number82834-16-0
WeightAverage: 368.4678
Monoisotopic: 368.231122144
Chemical FormulaC19H32N2O5
InChI KeyIPVQLZZIHOAWMC-QXKUPLGCSA-N
InChI
InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
IUPAC Name
(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
SMILES
[H][C@]12C[[email protected]](N(C(=O)[[email protected]](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Pharmacology
IndicationFor the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Structured Indications
PharmacodynamicsPerindopril is a nonsulfhydryl prodrug that is metabolized via first pass effect (62%) and systemic hydrolysis (38%) to perindoprilat, its active metabolite, following oral administration. Perindoprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of perindoprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionRapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%.
Volume of distributionNot Available
Protein bindingPerindoprilat, 10-20% bound to plasma proteins
Metabolism

Extensively metabolized, with only 4-12% of the dose recovered in urine following oral administration. Six metabolites have been identified: perindoprilat, perindopril glucuronide, perindoprilat glucuronide, a perindopril lactam, and two perindoprilat lactams. Only perindoprilat is pharmacologically active. Peridoprilat and perindoprilat glucuronide are the two main circulating metabolites.

SubstrateEnzymesProduct
Perindopril
Not Available
Perindopril Acyl-beta-D-glucuronideDetails
Perindopril
Not Available
PerindoprilatDetails
Perindopril
Not Available
Perindoprilat glucuronideDetails
Route of eliminationPerindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine.
Half lifePerindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.
Clearance
  • 219 – 362 mL/min [oral administration]
ToxicityThe most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Perindopril Action PathwayDrug actionSMP00152
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Perindopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Perindopril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Perindopril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Perindopril.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Perindopril is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Perindopril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Perindopril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Perindopril.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Perindopril.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Perindopril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Perindopril.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Perindopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Perindopril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Perindopril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Perindopril.Approved, Illicit, Investigational
AlprenololPerindopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Perindopril.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Perindopril.Experimental
AmifostinePerindopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Perindopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Perindopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Perindopril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Perindopril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Perindopril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Perindopril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Perindopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Perindopril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Perindopril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Perindopril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Perindopril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Perindopril is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Perindopril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Perindopril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Perindopril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Perindopril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Perindopril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Perindopril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Perindopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Perindopril is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Perindopril.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Perindopril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Perindopril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Perindopril.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Perindopril.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.Withdrawn
AzathioprinePerindopril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Perindopril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Perindopril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Perindopril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Perindopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Perindopril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Perindopril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Perindopril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Perindopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Perindopril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Benoxaprofen.Withdrawn
BepridilPerindopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Perindopril.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Perindopril.Approved
BethanidineBethanidine may increase the hypotensive activities of Perindopril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Perindopril is combined with Betulinic Acid.Investigational
BimatoprostPerindopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Perindopril.Approved
BoceprevirThe serum concentration of Perindopril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Perindopril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Perindopril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Perindopril.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Perindopril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Perindopril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Perindopril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Perindopril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Perindopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Perindopril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Perindopril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Perindopril is combined with Bupivacaine.Approved, Investigational
BupranololPerindopril may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Perindopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Perindopril.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Perindopril.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Perindopril.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Perindopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Perindopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Perindopril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Captopril.Approved
CarbamazepineThe metabolism of Perindopril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Perindopril is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Perindopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Perindopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Perindopril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Perindopril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Perindopril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Celecoxib.Approved, Investigational
CeliprololPerindopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Perindopril.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Perindopril.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Perindopril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Perindopril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Perindopril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Perindopril.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Perindopril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Perindopril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Perindopril.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Perindopril.Approved, Investigational
CiprofloxacinPerindopril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Perindopril.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Perindopril.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Perindopril.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Perindopril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Perindopril.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Perindopril is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Perindopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Perindopril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Perindopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Perindopril is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Perindopril.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Perindopril.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Perindopril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Perindopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Perindopril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Perindopril.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Perindopril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Perindopril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Perindopril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Perindopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Perindopril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Perindopril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Perindopril.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Perindopril.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Perindopril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Perindopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Perindopril.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Perindopril.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Perindopril.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Perindopril.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Perindopril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Perindopril.Investigational
DeserpidinePerindopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Perindopril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Perindopril.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Perindopril.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perindopril.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Perindopril.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Perindopril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Perindopril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Perindopril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Perindopril.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Perindopril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Perindopril.Approved
DihydralazinePerindopril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Perindopril.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Perindopril.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Perindopril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Perindopril.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Perindopril.Approved, Investigational, Vet Approved
DorzolamidePerindopril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Perindopril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Perindopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Perindopril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Perindopril.Approved, Investigational
DrospirenonePerindopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Droxicam.Approved
DuloxetinePerindopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Perindopril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Perindopril.Approved
E6201The risk or severity of adverse effects can be increased when Perindopril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Perindopril is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Perindopril.Approved
EfonidipinePerindopril may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Perindopril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Perindopril.Approved, Vet Approved
EnalaprilatPerindopril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Perindopril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Perindopril.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Perindopril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Perindopril.Approved
EpoprostenolPerindopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Perindopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Perindopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Perindopril.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Perindopril.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Perindopril.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Perindopril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Perindopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Perindopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Perindopril.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Perindopril.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Perindopril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Perindopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Perindopril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Perindopril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Perindopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Perindopril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Perindopril is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Perindopril.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Perindopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Perindopril is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Perindopril.Approved
exisulindThe risk or severity of adverse effects can be increased when Perindopril is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Perindopril.Approved
FelodipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenbufen.Approved
FenoldopamPerindopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Perindopril.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Perindopril.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Perindopril.Approved
FimasartanThe risk or severity of adverse effects can be increased when Perindopril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Perindopril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Perindopril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Perindopril.Approved
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Perindopril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Perindopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Perindopril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Perindopril.Approved, Vet Approved
GarlicThe serum concentration of Perindopril can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Perindopril.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Perindopril.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Perindopril.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Perindopril.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Perindopril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Perindopril.Approved
GuanethidinePerindopril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Perindopril is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Perindopril.Approved
HalothaneThe risk or severity of adverse effects can be increased when Perindopril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Perindopril.Approved, Investigational
HexamethoniumPerindopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Perindopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Perindopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Perindopril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Perindopril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Perindopril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Perindopril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Perindopril.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Perindopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Perindopril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Perindopril.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Perindopril.Approved
IloprostIloprost may increase the hypotensive activities of Perindopril.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Perindopril.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Perindopril.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Perindopril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Indapamide.Approved
IndenololPerindopril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Perindopril.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Perindopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Indoprofen.Withdrawn
IndoraminPerindopril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Perindopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Perindopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Perindopril.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Perindopril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Perindopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Perindopril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Perindopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Perindopril.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Perindopril.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Kebuzone.Experimental
KetanserinPerindopril may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Perindopril.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Perindopril.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Perindopril.Approved
LacidipinePerindopril may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Perindopril.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Perindopril.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Perindopril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Perindopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Perindopril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Perindopril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Perindopril is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Perindopril.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Perindopril.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Perindopril.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Perindopril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Perindopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Perindopril is combined with Levobupivacaine.Approved
LevodopaPerindopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Perindopril.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Perindopril.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Perindopril is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Perindopril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Perindopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Perindopril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Perindopril.Approved
LofexidinePerindopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Perindopril.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Perindopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Lumiracoxib.Approved, Investigational
MacitentanPerindopril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Perindopril is combined with Magnesium salicylate.Approved
ManidipinePerindopril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Perindopril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Perindopril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Perindopril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Perindopril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Perindopril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Perindopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Perindopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Perindopril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Perindopril.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Perindopril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Perindopril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Perindopril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Perindopril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Perindopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Perindopril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Perindopril.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Perindopril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Perindopril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Perindopril.Approved, Investigational
MetyrosinePerindopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilPerindopril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Perindopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Perindopril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Perindopril.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Perindopril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Perindopril.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Perindopril.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Perindopril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Perindopril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Perindopril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Perindopril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Perindopril.Approved, Investigational
MoxonidinePerindopril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Perindopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Perindopril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Perindopril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Perindopril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Perindopril is combined with Naftifine.Approved
NaftopidilPerindopril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Perindopril.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Perindopril.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Perindopril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Perindopril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Perindopril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Perindopril.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Perindopril.Approved
NepafenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Perindopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Perindopril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Perindopril.Approved
NicorandilNicorandil may increase the hypotensive activities of Perindopril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Perindopril is combined with Niflumic Acid.Approved
NiguldipinePerindopril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Perindopril.Approved, Investigational
NilvadipinePerindopril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Perindopril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Perindopril.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Perindopril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Perindopril.Approved
NitrendipinePerindopril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Perindopril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Perindopril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Perindopril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Perindopril.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Perindopril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Perindopril.Approved
ObinutuzumabPerindopril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Perindopril.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Perindopril.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Perindopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Perindopril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Olsalazine.Approved
OmapatrilatPerindopril may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Perindopril.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Perindopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Perindopril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Perindopril.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxaprozin.Approved
OxprenololPerindopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Perindopril.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Perindopril.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Perindopril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Perindopril.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Perindopril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Perindopril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Perindopril.Approved, Vet Approved
PentoliniumPerindopril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Perindopril.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Perindopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Perindopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Perindopril.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Perindopril.Approved
PhenoxybenzaminePerindopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Perindopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Perindopril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Perindopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Perindopril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Perindopril.Approved
PinacidilPerindopril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Perindopril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Perindopril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Perindopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Perindopril.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Perindopril.Withdrawn
PolythiazidePerindopril may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Perindopril.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Perindopril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Perindopril.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Perindopril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Perindopril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Perindopril.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Perindopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Perindopril.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Perindopril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Perindopril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Perindopril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Perindopril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Perindopril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Perindopril.Approved
PTC299The risk or severity of adverse effects can be increased when Perindopril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Perindopril.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Perindopril.Approved
QuinineQuinine may increase the hypotensive activities of Perindopril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Perindopril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Perindopril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Perindopril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Perindopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Perindopril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Perindopril.Approved
RescinnaminePerindopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perindopril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Perindopril.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Perindopril.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Perindopril.Approved, Investigational
RilmenidinePerindopril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Perindopril.Approved
RisperidonePerindopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Perindopril.Approved, Investigational
RituximabPerindopril may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Perindopril.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Perindopril.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Perindopril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Perindopril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Perindopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Perindopril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Perindopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Perindopril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Perindopril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Perindopril.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Perindopril.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Perindopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Perindopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Perindopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Perindopril.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Perindopril.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Perindopril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Perindopril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Perindopril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Perindopril.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Perindopril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Perindopril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Perindopril.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Perindopril.Approved, Investigational
SitaxentanPerindopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Perindopril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Perindopril is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Perindopril.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Perindopril.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Perindopril.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Perindopril.Experimental
SpiraprilPerindopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Perindopril.Approved
SRT501The risk or severity of adverse effects can be increased when Perindopril is combined with SRT501.Investigational
St. John's WortThe metabolism of Perindopril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Perindopril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Perindopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Perindopril.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Perindopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Perindopril.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Perindopril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Perindopril.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Perindopril.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Perindopril.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Perindopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Perindopril.Approved, Investigational
TemocaprilPerindopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Perindopril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Perindopril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Perindopril is combined with Teriflunomide.Approved
TerlipressinPerindopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Perindopril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Perindopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Perindopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Perindopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Perindopril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Tiaprofenic acid.Approved
TibolonePerindopril may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Perindopril.Approved
TicrynafenPerindopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Perindopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Perindopril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Perindopril.Approved
TipranavirThe serum concentration of Perindopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Perindopril.Approved
TolazolinePerindopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Perindopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Perindopril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Perindopril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Perindopril.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Perindopril.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Perindopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Perindopril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Perindopril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Perindopril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Perindopril.Approved
TravoprostTravoprost may increase the hypotensive activities of Perindopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Perindopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Perindopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Perindopril.Approved
TrichlormethiazidePerindopril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPerindopril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPerindopril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Perindopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Perindopril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Perindopril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Perindopril.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Perindopril.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Perindopril.Approved
UnoprostonePerindopril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Perindopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Perindopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Perindopril.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Perindopril.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Perindopril.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Perindopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Perindopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Perindopril.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Perindopril.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Perindopril.Approved, Investigational
VinpocetinePerindopril may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Perindopril.Approved
XylometazolinePerindopril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Perindopril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Perindopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Perindopril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Perindopril is combined with Zomepirac.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of perindopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of perindopril.
  • Perindopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take without regard to meals.
References
Synthesis Reference

Michel Vincent, Jean Baliarda, Bernard Marchand, Georges Remond, “Process for the industrial synthesis of perindopril.” U.S. Patent US4914214, issued April 03, 1990.

US4914214
General References
  1. Hurst M, Jarvis B: Perindopril: an updated review of its use in hypertension. Drugs. 2001;61(6):867-96. [PubMed:11398915 ]
  2. Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K, Wesotowska T: Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004 Oct;14(5):259-69. [PubMed:15673060 ]
  3. Parker E, Aarons L, Rowland M, Resplandy G: The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur J Pharm Sci. 2005 Sep;26(1):104-13. [PubMed:15982858 ]
  4. Simpson D, Noble S, Goa KL: Perindopril: in congestive heart failure. Drugs. 2002;62(9):1367-77; discussion 1378-9. [PubMed:12076191 ]
  5. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, Komune S: Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73. Epub 2004 Jul 27. [PubMed:15449186 ]
  6. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001 Apr;7(4):1073-8. [PubMed:11309359 ]
External Links
ATC CodesC10BX11C09AA04C09BX02C09BB04C09BA04C09BX01
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelDownload (149 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.8411
Caco-2 permeable-0.7871
P-glycoprotein substrateSubstrate0.6826
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IIInhibitor0.8589
Renal organic cation transporterNon-inhibitor0.919
CYP450 2C9 substrateNon-substrate0.8638
CYP450 2D6 substrateNon-substrate0.8542
CYP450 3A4 substrateSubstrate0.549
CYP450 1A2 substrateNon-inhibitor0.8796
CYP450 2C9 inhibitorNon-inhibitor0.8612
CYP450 2D6 inhibitorNon-inhibitor0.9088
CYP450 2C19 inhibitorNon-inhibitor0.8375
CYP450 3A4 inhibitorNon-inhibitor0.7142
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5951
Ames testNon AMES toxic0.8814
CarcinogenicityNon-carcinogens0.9266
BiodegradationNot ready biodegradable0.9082
Rat acute toxicity1.9432 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9839
hERG inhibition (predictor II)Non-inhibitor0.8678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott products inc
  • Aurobindo pharma ltd
  • Ivax pharmaceuticals inc
  • Lupin ltd
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2 mg/1
TabletOral8 mg
TabletOral10 mg
TabletOral2.5 mg
TabletOral5 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral2.5 mg
Tablet, orally disintegratingOral5 mg
TabletOral2 mg
TabletOral4 mg
TabletOral
TabletOral4 mg/1
TabletOral8 mg/1
Prices
Unit descriptionCostUnit
Aceon 8 mg tablet3.14USD tablet
Perindopril erbumine 8 mg tablet2.8USD tablet
Aceon 4 mg tablet2.58USD tablet
Perindopril erbumine 4 mg tablet2.3USD tablet
Aceon 2 mg tablet2.22USD tablet
Perindopril erbumine 2 mg tablet1.98USD tablet
Coversyl 8 mg Tablet1.23USD tablet
Coversyl 4 mg Tablet0.88USD tablet
Coversyl 2 mg Tablet0.7USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341196 No2001-03-062018-03-06Canada
CA2473205 No2010-05-182023-01-22Canada
US5162362 No1992-11-102009-11-10Us
US6696481 No2003-04-152023-04-15Us
US7846961 No2009-10-052029-10-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP0.56ALOGPS
logP0.63ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)3.79ChemAxon
pKa (Strongest Basic)5.48ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity95.69 m3·mol-1ChemAxon
Polarizability40 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Indole or derivatives
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Fatty acid ester
  • Fatty acyl
  • Dicarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Alfakih K, Hall AS: Perindopril. Expert Opin Pharmacother. 2006 Jan;7(1):63-71. [PubMed:16370923 ]
  2. Brugts JJ, Ferrari R, Simoons ML: Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. [PubMed:19379059 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Mehta A, Iyer L, Parmar S, Shah G, Goyal R: Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol. 2010 May;88(5):595-600. doi: 10.1139/y10-026. [PubMed:20555429 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:46